Mahar Patrick, Sengupta Shomik, Ludlow Karinne, Corcoran Niall
Urology Unit, The Alfred, Melbourne, Victoria.
Aust Fam Physician. 2010 Aug;39(8):598-600.
The uncertainty regarding prostate specific antigen (PSA) screening for prostate cancer has not been alleviated, despite recent randomised controlled trials and position statements released by authoritative bodies.
This article summarises authoritative position statements by representative bodies in Australia and describes legal considerations for a general practitioner when deciding whether to order PSA tests as a screening tool for prostate cancer.
Prostate specific antigen as a primary screening tool is generally not endorsed by most authoritative bodies in Australia, with the exception in some circumstances for men 55-69 years of age. Where asymptomatic patients request a PSA be undertaken, a GP can be justified both to order a PSA test or not to, such is the context of peer professional opinion provisions in Australian legislation and conflicting authoritative position statements regarding PSA.Where there is still ongoing uncertainty, the matter may be appropriately referred for specialist consideration.
尽管最近有随机对照试验以及权威机构发布的立场声明，但前列腺癌前列腺特异性抗原（PSA）筛查的不确定性仍未得到缓解。
本文总结了澳大利亚代表性机构的权威立场声明，并描述了全科医生在决定是否将PSA检测作为前列腺癌筛查工具时的法律考量。
在澳大利亚，大多数权威机构通常不认可将前列腺特异性抗原作为主要筛查工具，55至69岁男性在某些情况下除外。对于无症状患者要求进行PSA检测的情况，全科医生决定是否进行PSA检测均合理，这是澳大利亚立法中同行专业意见条款以及关于PSA的相互矛盾的权威立场声明所导致的。在不确定性仍然存在的情况下，该问题可适当提交给专科医生考虑。
